Your browser doesn't support javascript.
loading
[A study on quality of Paridis Rhizoma and consideration on standards of Paridis Rhizoma in Chinese Pharmacopoeia].
Jia, Tian-Ying; Zhang, Xiao-Nan; Su, Tai; Yang, Xiao-Yan; Wang, Hai-Li; Xin, Jie-Ping; Liu, Meng-Nan; Wang, Jing-Kun; Li, Xiang-Ri.
Affiliation
  • Jia TY; School of Chinese Pharmacy, Beijing University of Chinese Medicine Beijing 102488, China.
  • Zhang XN; Yunnan Baiyao Group Limited Ltd. Kunming 650500, China.
  • Su T; Yunnan Baiyao Group Limited Ltd. Kunming 650500, China.
  • Yang XY; Yunnan Baiyao Group Limited Ltd. Kunming 650500, China.
  • Wang HL; School of Chinese Pharmacy, Beijing University of Chinese Medicine Beijing 102488, China.
  • Xin JP; School of Chinese Pharmacy, Beijing University of Chinese Medicine Beijing 102488, China.
  • Liu MN; School of Chinese Pharmacy, Beijing University of Chinese Medicine Beijing 102488, China.
  • Wang JK; Yunnan Baiyao Group Limited Ltd. Kunming 650500, China.
  • Li XR; School of Chinese Pharmacy, Beijing University of Chinese Medicine Beijing 102488, China.
Zhongguo Zhong Yao Za Zhi ; 45(10): 2425-2430, 2020 May.
Article in Zh | MEDLINE | ID: mdl-32495602
ABSTRACT
Thin layer chromatography, high performance liquid chromatography and multivariate statistical analysis were integrated in current study to provide a basis for the quality evaluation and the standard improvement of Paridis Rhizoma(Chinese name Chong-lou). The results demonstrated that the primary saponins in the two authorized sources of Paridis Rhizoma were polyphyllinsⅠ, Ⅱ and Ⅶ, while the rhizome of Trillium tschonoskii an adulterant of Paridis Rhizoma was rich of polyphyllin Ⅵ. Therefore, the apparent content of polyphyllin Ⅵ plays a determinant role towards the source authentication of raw materials and decoction slices of Paridis Rhizoma, whose adulterants frequently occur in the market. Moreover, the contents of polyphyllin Ⅵ in the two authorized sources could meet the requirements of Chinese Pharmacopoeia. Therefore, we suggested that polyphyllin Ⅵ should not be omitted from the quality standard of Paridis Rhizoma in the Chinese Pharmacopoeia, and on the other side, polyphyllinsⅠ, Ⅱ and Ⅶ should be the eligible quality indicators. The study aims to sound information and evidences for the quality evaluation of Paridis Rhizoma, and also to provide a theoretical basis for the standard revision of Paridis Rhizoma in the future Chinese Pharmacopoeia.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Main subject: Saponins / Drugs, Chinese Herbal / Trillium Language: Zh Journal: Zhongguo Zhong Yao Za Zhi Year: 2020 Type: Article Affiliation country: China

Full text: 1 Database: MEDLINE Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Main subject: Saponins / Drugs, Chinese Herbal / Trillium Language: Zh Journal: Zhongguo Zhong Yao Za Zhi Year: 2020 Type: Article Affiliation country: China